Advances in the treatment of Crohn's disease

被引:57
作者
Egan, LJ [1 ]
Sandborn, WJ [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
关键词
D O I
10.1053/j.gastro.2004.01.062
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The medical therapy of Crohn's disease has improved considerably in recent years. In large part, this is due to the introduction of new efficacious agents, both "biologics" and traditional small molecules. Further study of older drugs has also advanced our ability to devise the optimum approach to individual Crohn's disease patients by better clarifying the benefits, adverse effects, and means to optimize doses of established medications. In this review, we present an evidence-based approach to the medical management of active Crohn's disease, Crohn's disease in remission, and perianal Crohn's disease that emphasizes recent advances that have come from the results of randomized controlled clinical trials.
引用
收藏
页码:1574 / 1581
页数:8
相关论文
共 57 条
[1]   A CONTROLLED DOUBLE-BLIND MULTICENTER STUDY OF THE EFFECTIVENESS OF 5-AMINOSALICYLIC ACID IN PATIENTS WITH CROHNS-DISEASE IN REMISSION [J].
ARBER, N ;
ODES, HS ;
FIREMAN, Z ;
LAVIE, A ;
BROIDE, E ;
BUJANOVER, Y ;
BECKER, S ;
POMERANTZ, I ;
MOSHKOWITZ, M ;
PATZ, J ;
GILAT, T .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 (03) :203-206
[2]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[3]   PLACEBO-CONTROLLED TRIAL OF ORAL 5-ASA IN RELAPSE PREVENTION OF CROHNS-DISEASE [J].
BRIGNOLA, C ;
IANNONE, P ;
PASQUALI, S ;
CAMPIERI, M ;
GIONCHETTI, P ;
BELLUZZI, A ;
BASSO, O ;
MIGLIOLI, M ;
BARBARA, L .
DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (01) :29-32
[4]   SEXUAL PROBLEMS AMONG MARRIED ILEOSTOMISTS - SURVEY CONDUCTED BY ILEOSTOMY-ASSOCIATION OF GREAT BRITAIN AND IRELAND [J].
BURNHAM, WR ;
LENNARDJONES, JE ;
BROOKE, BN .
GUT, 1977, 18 (08) :673-677
[5]   Oral budesonide is as effective as oral prednisolone in active Crohn's disease [J].
Campieri, M ;
Ferguson, A ;
Doe, W ;
Persson, T ;
Nilsson, LG ;
Malchow, H ;
Prantera, C ;
Mani, V ;
OMorain, C ;
Selby, W ;
Pallone, F ;
diPietralata, MM ;
Sjodahl, R ;
Florin, T ;
Smith, P ;
Bianchi, P ;
Lofberg, R ;
Rutgeerts, P ;
Smallwood, R ;
Lamers, HW ;
TasmanJones, C ;
Hunter, JO ;
Hodgson, H ;
Danielsson, A ;
Lee, FI ;
Piacitelli, G ;
Giovanni, S ;
Ellis, A ;
Weir, DG .
GUT, 1997, 41 (02) :209-214
[6]   A CONTROLLED DOUBLE-BLIND-STUDY OF AZATHIOPRINE IN THE MANAGEMENT OF CROHNS-DISEASE [J].
CANDY, S ;
WRIGHT, J ;
GERBER, M ;
ADAMS, G ;
GERIG, M ;
GOODMAN, R .
GUT, 1995, 37 (05) :674-678
[7]   Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease [J].
Cortot, A ;
Colombel, JF ;
Rutgeerts, P ;
Lauritsen, K ;
Malchow, H ;
Hämling, J ;
Winter, T ;
Van Gossum, A ;
Persson, T ;
Pettersson, E .
GUT, 2001, 48 (02) :186-190
[8]   Controlled trial of oral 5-aminosalicyclic acid for the prevention of early relapse in Crohn's disease [J].
DeFranchis, R ;
Omodei, P ;
Ranzi, T ;
Brignola, C ;
Rocca, R ;
Prada, A ;
Pera, A ;
Vecchi, M ;
DelPiano, M ;
Ferrara, A ;
Belloli, C ;
Piodi, L ;
Framarin, L ;
Astegiano, M ;
Riccioli, FA ;
Meucci, G .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (05) :845-852
[9]   The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study [J].
Faubion, WA ;
Loftus, EV ;
Harmsen, WS ;
Zinsmeister, AR ;
Sandborn, WJ .
GASTROENTEROLOGY, 2001, 121 (02) :255-260
[10]   A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease [J].
Feagan, BG ;
Fedorak, RN ;
Irvine, EJ ;
Wild, G ;
Sutherland, L ;
Steinhart, AH ;
Greenberg, GR ;
Koval, J ;
Wong, CJ ;
Hopkins, M ;
Hanauer, SB ;
McDonald, JWD .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (22) :1627-1632